AVROBIO, Inc. (AVRO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Erik John Ostrowski M.B.A. | President, Interim CEO, CFO & Treasurer | 1.25M | -- | 1972 |
| Dr. Azadeh Golipour Ph.D. | Chief Technology Officer | 1.01M | -- | 1980 |
| Dr. Essra Ridha FFPM, M.D. | Chief Medical Officer | 1.12M | -- | 1983 |
| Mr. Jeffrey Medin Ph.D. | Scientific Founder | -- | -- | -- |
| Mr. Steven N. Avruch J.D. | Chief Legal Officer & Secretary | 506.68k | -- | 1962 |
| Mr. Scott Gottesman | Vice President of Human Resource | -- | -- | -- |
| Ms. Kirsten Dupuis | Chief of Staff | -- | -- | -- |
AVROBIO, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Recent Events
- Apr 15, 2024S-4/A: Offering RegistrationsSee Full Filing
- Apr 04, 2024425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsSee Full Filing
- Mar 26, 2024S-4/A: Offering RegistrationsSee Full Filing
- Mar 14, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 14, 2024S-4: Offering RegistrationsSee Full Filing